论文部分内容阅读
目的评价经皮冠脉介入治疗(PCI)前应用β-受体阻滞剂对病人的保护作用。方法对青岛大学医学院附属医院1997~2004年间行PCI治疗病人210例,随机分为β-受体阻滞剂组(105例)及对照组(105例)。分别于术前、术后6~8h及16~24h抽取血标本检测心肌肌酸激酶(CK-MB)、肾上腺素(E)、去甲肾上腺素(NE)值,并随访病人院内、院外1年心脏事件的发生率。结果(1)两组间CK-MB、E、NE值均无统计学意义。同组间,不同时间内CK-MB、E、NE值差异亦无显著性。(2)服β-受体阻滞剂组院内病死率较未服者低(2.1%比4.1%),1年随访β-受体阻滞剂组院内病死率亦较未服者低(5.5%比7.1%)。结论PCI治疗前应用β-受体阻滞剂对病人有保护作用。
Objective To evaluate the protective effect of β-blocker on patients before percutaneous coronary intervention (PCI). Methods Totally 210 patients underwent PCI from 1997 to 2004 in Affiliated Hospital of Qingdao University Medical College were randomly divided into β-blocker group (105 cases) and control group (105 cases). Blood samples were collected before surgery, 6-8h and 16-24h respectively to detect the levels of CK-MB, NE and NE, and the follow-up of patients in hospital, hospital 1 The incidence of annual cardiac events. Results (1) CK-MB, E, NE between the two groups were not statistically significant. The same group, at different times CK-MB, E, NE value difference was not significant. (2) The in-hospital mortality rate in the β-blocker group was lower than that in the unobserved group (2.1% vs 4.1%). The 1-year follow-up mortality rate in the β-blocker group was also lower than that of the non-responder group % Than 7.1%). Conclusion The application of β-blockers before PCI has a protective effect on the patients.